Feed NRXP
NR

NRx Pharmaceuticals, Inc.

NRXP · NASDAQ

$3.40 -1.16% (-$0.04)
1M -0.87%
Market Cap $58.8M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$2.29

32.6% downside

Trenutna cena

$3.4

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica NRXP trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/S 17.32x
EV/EBITDA N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
12 /100
Weak
Net margin 691.81%
Op. margin 588.24%
FCF margin 609.05%
Quality
2 /100
Poor
ROA 68.74%
Asset turnover 0.10x
ROIC 1,855.48%
Debt
12 /100
High
Int. coverage -19.52x
Current ratio 0.86x
Net debt/EBITDA N/A
Stability
1 /100
Unstable
EPS volatility 349.46%
Profitable years 0
Beta 2.19x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NRXP
Online

O podjetju

NRx Pharmaceuticals, Inc. (NRXP) is a pharmaceutical company focused on research and development of new drugs for the treatment of serious diseases. The company specializes in therapeutic approaches for diseases that currently lack effective treatments or have inadequate treatment options. NRx Pharmaceuticals emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment possibilities. Their drugs are aimed at potential treatments for diseases in areas such as neurology, oncology, infectious diseases, and more. The company is actively developing drugs and conducting clinical trials to confirm the effectiveness and safety of their products. NRx Pharmaceuticals aims to bring new drugs to the market that can make a significant improvement for patients with serious diseases. NRx Pharmaceuticals, Inc. (NRXP) shares may be an attractive investment opportunity for investors interested in the pharmaceutical sector and seeking an investment in a company focused on innovative therapeutic approaches for serious diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jonathan C. Javitt

Employees

29

Headquarters

Wilmington

Prihajajoči dogodki

13 NOV.

Earnings

Upcoming earnings report

60d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.